Radioactive seeds plus immunotherapy: a new hope for Hard-to-Treat head and neck cancer?

NCT ID NCT05047094

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial is testing a new approach for people with head and neck cancer that has come back or spread and cannot be removed. It combines a device called DaRT, which is a tiny radioactive seed placed directly into the tumor, with the immunotherapy drug pembrolizumab (Keytruda). The goal is to see if this combination can shrink tumors and control the disease. About 48 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Diffusing Alpha Radiation Emitters Therapy (DaRT) device and pembrolizumab (Keytruda)
What this could lead to
If it works, this could offer a new treatment option for people with head and neck cancer that has come back or spread and cannot be removed by surgery.
What could go wrong
This is an early-stage trial with only 48 participants, so results may not apply to everyone. The combination of radiation and immunotherapy may cause side effects like inflammation or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sharett institute, Hadassah University Hospital - Ein-Kerem

    RECRUITING

    Jerusalem, 91120, Israel

  • Sheba Medical Center

    RECRUITING

    Ramat Gan, Israel

  • Tel-Aviv Medical Center

    NOT_YET_RECRUITING

    Tel Aviv, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.